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Fatty acids (FA) and FA-derived metabolites have long been implicated in the development of insulin
resistance and type 2 diabetes. Surprisingly, application of metabolomics technologies has revealed that
branched-chain amino acids (BCAA) and related metabolites are more strongly associated with insulin
resistance than many common lipid species. Moreover, the BCAA-related signature is predictive of incident
diabetes and intervention outcomes and uniquely responsive to therapeutic interventions. Nevertheless, in
animal feeding studies, BCAA supplementation requires the background of a high-fat diet to promote
insulin resistance. This Perspective develops a model to explain how lipids and BCAA may synergize to
promote metabolic diseases.Introduction
The pandemic of obesity that burdens the world population is
well documented. In the United States, more than 65% of adults
are characterized as overweight or obese (Flegal et al., 2002).
This epidemic of obesity is linked to increasing incidence of
chronic diseases such as type 2 diabetes, cardiovascular
disease, and cancer. A common perception is that this constel-
lation of maladies is driven principally by increased consumption
of fat in the diet, and accordingly, other Perspectives in this
compendium are focused on the impact of excess lipids on
various cellular functions, including mitochondrial metabolism,
endoplasmic stress responses, inflammation, and generation
of reactive oxygen species. However, numerous recent reports
have described a particularly strong association of branched-
chain and aromatic amino acids with metabolic disease. There-
fore, this Perspective reviews these recent findings and then
focuses on the potential role of these metabolites in disease
pathogenesis, including a discussion of interactions between
amino acids and lipids in development of metabolic disorders.
A strong relationship between glucose and lipid metabolism
has been recognized for decades, with key features of this
regulatory dynamic unveiled by the pioneering studies of Sir
Phillip Randle and J. Denis McGarry (Randle, 1998; McGarry,
2002). Randle showed that the surge in lipolysis and resultant
increase in circulating free fatty acids in the fasted state contrib-
utes to increased reliance of tissues on fatty acid oxidation
to provide energy. Glucose oxidation is reduced under these
conditions in part via the generation of byproducts of fatty acid
oxidation that suppress key steps of glucose metabolism.
Conversely, McGarry demonstrated that increased availability
of glucose and insulin in the fed state leads to production of ma-
lonyl CoA, a potent allosteric inhibitor of fatty acid oxidation.
Overnutrition results in perturbation of these elegant reciprocal
control mechanisms, leading to a condition termed ‘‘metabolic
inflexibility’’ (Kelley and Mandarino, 2000). A subject debated in
other Perspectives in this compendium is whether the metabolic606 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.inflexibility and insulin resistance of obese states is due to
intrinsic mitochondrial deficiency and consequent accumulation
of bioactive lipid species that interfere with insulin signaling
(Savage et al., 2007), or is due instead to ‘‘overloading’’ of nor-
mally active mitochondria with lipid substrates, leading to mito-
chondrial dysfunction and activation of alternative pathways
for impairment of insulin action (Koves et al., 2008). The latter
model seems particularly compatible with the emergent role of
certain amino acids in development of insulin resistance and
type 2 diabetes and will therefore be a focus here.
Comprehensive metabolic profiling, also known as ‘‘metabo-
lomics,’’ has recently provided unique insights into mechanisms
underlying development of insulin resistance (Bain et al., 2009).
For example, metabolic profiling of muscle samples from normal
rats fed on a high-fat (HF) compared to a standard chow diet, or
from obese and insulin-resistant Zucker diabetic fatty (fa/fa)
compared to lean Zucker rats, reveals accumulation of a broad
array of acylcarnitine species, which report on the pool of mito-
chondrial acyl CoA metabolites and the b-oxidative pathway
(Koves et al., 2005, 2008). Several studies demonstrate that
feeding of a HF diet to humans or rodents and culture of muscle
cells in the presence of high levels of fatty acids cause clear
induction of genes of b-oxidation, but with either no effect or
a decrease in expression of enzymes involved in the tricarboxylic
acid (TCA) cycle or oxidative phosphorylation (Koves et al., 2005;
Sparks et al., 2005). Fatty acid culture or feeding of a HF diet also
causes a decrease in expression of peroxisome proliferator-acti-
vated receptor gamma coactivator 1a (PGC-1a) and an increase
in acylcarnitine levels in muscle cells. Two weeks of exercise
intervention in HF-fed mice results in increased PGC-1a expres-
sion, lowering of acylcarnitines in muscle, and normalization
of insulin sensitivity (Koves et al., 2005). Finally, overexpression
of PGC-1a in muscle cells also causes increased expression of
TCA cycle enzymes. Taken together, these findings have led
Muoio and associates to suggest that HF feeding leads to the
appropriate adaptive response of an increase in enzymes of fatty
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matched in sedentary animals or humans by a parallel increase
in enzymes of the TCA cycle. This disconnect results in accumu-
lation of incompletely oxidized lipid species inmitochondria (rep-
resented by the acylcarnitines) and a decrease in multiple TCA
cycle intermediates. The model further holds that accumulation
of incompletely oxidized substrates causes mitochondrial
stress, leading to impaired insulin action (Koves et al., 2005,
2008; Muoio and Newgard, 2008).
Emergence of Novel Associations of Branched-Chain
Amino Acids with the Incidence, Progression,
and Therapy of Human Metabolic Diseases
Metabolomics has also been applied to human disease studies.
Using targeted gas chromatography/mass spectrometry and
tandem mass spectrometry coupled with biochemical methods,
>100 analytes were measured in plasma samples from obese
(BMI 37) and insulin-resistant versus lean (BMI 23) and insulin-
sensitive subjects, and data were analyzed by principal compo-
nents analysis (Newgard et al., 2009). Five principal components
were found to describemost of the variance in the data, including
several lipid-related components (e.g., long-chain fatty acids
and ketone metabolites, medium-chain acylcarnitines), but
surprisingly, the component most strongly associated with
insulin sensitivity (HOMA score) was not lipid related, but rather
comprised of the branched-chain amino acids (BCAA; Val,
Leu/Ile), the aromatic amino acids (Phe, Tyr), C3 and C5 acylcar-
nitines, as well as Glx (mostly Glu with some Gln) and Ala. The
preferential association of this BCAA-related metabolite cluster
with insulin resistance was confirmed in a cross-sectional study
of sedentary, metabolic syndrome subjects, using the frequently
sampled glucose tolerance test to measure insulin sensitivity
(Huffman et al., 2009), and in cohorts of Chinese and Asian-
Indian men in Singapore in which BMI was matched at around
24 (Tai et al., 2010). These studies demonstrate the strong and
preferential association of the BCAA-related metabolite cluster
and insulin resistance in studies of different design (case-control
or cross-sectional) and across multiple ethnic groups and
geographical locales. A subsequent study also demonstrated
a strong association of a similar BCAA-related metabolite cluster
with coronary artery disease in both a reference and validation
cohort, with this association persisting even after correction for
type 2 diabetes and other clinical variables (Shah et al., 2010).
In addition to the strong correlation of BCAA and related
metabolites with metabolic disease, recent studies have
demonstrated that these analytes can be predictive of disease
progression and intervention outcomes. For example, we
recently studied 500 obese subjects from the weight loss main-
tenance (WLM) trial (Svetkey et al., 2008), in which blood
samples were taken at baseline, followed by a 6 month behav-
ioral/dietary (DASH diet) intervention. The amount of weight
lost over the 6 months of intervention was very poorly correlated
with improvement in homeostatic model assessment (HOMA)
score. In contrast, targeted metabolic profiling of plasma
samples collected at baseline revealed that the BCAA-related
principal component factor score was a strong predictor of
improvement in insulin sensitivity with intervention, whereas
lipid-related factors had no predictive association (Shah et al.,
2012). Metabolomics has also been applied to baseline plasmasamples from 189 subjects in the Framingham longitudinal
cohort that developed type 2 diabetes over as much as 12 years
of follow-up, compared to 189 control subjects that did not
develop diabetes despite being matched for weight, lipid profile,
and other clinical variables (Wang et al., 2011). The five metab-
olites with the strongest association with incident diabetes were
Leu, Ile, Val, Phe, and Tyr, remarkably similar to the composition
of the metabolite principal component found to associate with
metabolic diseases and conditions in our studies. The ability of
these metabolites to predict incident diabetes was confirmed
in a second group of subjects available from the Malmo cohort
(Wang et al., 2011).
Finally, there is evidence that changes in BCAA levels may
correlate with the efficacy of interventions for affecting improve-
ment inmetabolic control. Thus, our group has shown that obese
subjects undergoing gastric bypass (GBP) surgery have a much
more dramatic decline in circulating BCAA, C3 and C5 acylcarni-
tines, Phe, and Tyr than found in response to dietary intervention,
despite equal weight loss in the two study groups (Laferre`re
et al., 2011). This is significant because GBP causes greater
improvement in glucose homeostasis than dietary intervention
(Laferre`re et al., 2011; Clifton, 2010). Moreover, the efficacy
of a set of thiazolidinedione (TZD) drugs for controlling glucose
homeostasis in Zucker-obese rats has been correlated with their
unique ability to enhance expression of the BCAA catabolic
pathway in adipose tissue (Hsiao et al., 2011), as discussed
further below.
It is important to note that associations of BCAA and other
amino acids with insulin resistance and type 2 diabetes have
been noted over more than 30 years by Cahill, Felig, Marliss,
and others (Felig et al., 1969, 1974; Gougeon et al., 2008).
However, by taking a more broad-based metabolomics
approach, the newer findings provide several insights that
move the field beyond these important historical observations.
First, principal components analysis demonstrates that BCAA
and aromatic amino acids form an independent clustered vari-
able that also includes byproducts of BCAA catabolism such
as Glu, Ala, and C3 and C5 acylcarnitines, suggesting that the
meaningful association is not with BCAA per se, but rather with
altered flux through the BCAA catabolic pathway. Second, the
global analysis conducted by several groups demonstrates
a stronger association of BCAA and related metabolites with
insulin resistance and type 2 diabetes than with other metabolite
clusters, including lipid-related clusters. Third, the newer studies
demonstrate the potential prognostic power of this group of
analytes. Taken together, the combined historical and newer
studies show that BCAA and related metabolites are associated
with insulin resistance, diabetes, and CAD, predictive of dia-
betes development, predictive of intervention outcomes, and
highly and uniquely responsive to therapeutic interventions.
The metabolites embodied in the BCAA-related principal
components that so consistently associate with insulin resis-
tance and metabolic disease have a biochemical as well as
statistical connection (Figure 1). Thus, Glu is produced in the
first step of BCAA catabolism, transamination by the mitochon-
drial form of BCAA transaminase (BCATm). C5 acylcarnitines
are comprised of a-methylbutyryl and isovalerylcarnitine
species, intermediates in mitochondrial Ile and Leu catabolism,
respectively. C3 acylcarnitine reflects the propionyl CoA pool,Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 607
Figure 1. Pathways of Branched-Chain Amino Acid Catabolism
Shown in blue are the reactions that produce metabolites found in the BCAA-related principal component that associates with insulin resistance and other
metabolic diseases.
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not the only metabolic fuels that can generate C3 and C5
acylcarnitines (for example, methionine is also degraded to
propionyl CoA), but a direct link of BCAA to C3 and C5 acylcar-
nitines is demonstrated by a rise in circulating and tissue levels
of these metabolites in response to BCAA supplementation
(Newgard et al., 2009). Accumulation of Glu may increase trans-
amination of pyruvate to Ala. Finally, the elevation in the
aromatic amino acids Phe and Tyr may be explained by the
fact that Trp, Phe, Tyr, Leu, Ile, and Val compete for transport
into mammalian cells by the large neutral amino acid transporter
(LAT1) (Fernstrom, 2005).608 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.Potential Cause-Effect Relationships between BCAA
and Metabolic Diseases
Recent studies demonstrating strong associations of BCAA and
relatedmetabolites with disease, disease progression, and inter-
vention outcomes suggest a possible cause/effect relationship
between these metabolites and disease development. More-
over, the large body of extant literature implicating fatty acids
and other lipids in development of tissue dysfunction and meta-
bolic disease raises the possibility that these abnormalitiesmight
be driven by combined effects of lipids and BCAA. To begin to
test these ideas, we fed Wistar rats on HF, HF + BCAA, or stan-
dard chow (SC) diets (Newgard et al., 2009). Interestingly,
Figure 2. Acylcarnitines in Skeletal Muscle in Rats Fed on Various Diets for 12 Weeks
SC, standard chow; SC/BCAA, standard chow supplemented with branched-chain amino acids (Val, Leu, Ile); HF, high-fat diet (35% calories from fat); HF/BCAA,
HF diet supplemented with branched-chain amino acids. Inset: C3 and C5 acylcarnitines in rats fed on various diets. Data adapted from Newgard et al., 2009.
Cell Metabolism
Perspectiveanimals fed on the HF + BCAA diet consumed less food than the
HF group, consistent with reports of reduced food intake in
response to intracerebroventricular injection of Leu in mice
(Cota et al., 2006). Despite a lower rate of food intake and
body weight gain equivalent to the SC group, HF + BCAA rats
were equally insulin resistant as HF rats, as demonstrated by
glucose and insulin tolerance tests and by impaired insulin
signaling in liver and muscle (Newgard et al., 2009). Pair-feeding
of HF diet to match the food intake of HF + BCAA animals or
feeding of SC + BCAA did not cause insulin resistance. Insulin
resistance induced by HF + BCAA was accompanied by chronic
activation of mammalian target of rapamycin (mTOR), P70-S6
kinase 1 (S6K-1), c-Jun N-terminal kinase (JNK), and phosphor-
ylation of insulin receptor substrate-1 (IRS1(Ser307)) and was
reversed by the mTOR inhibitor rapamycin. These data suggest
an interaction between excess fat and BCAA in development of
insulin resistance and demonstrate a contribution of BCAA to
impaired glucose homeostasis that can occur independently of
body weight. Although our studies with rapamycin suggest
a role for mTOR and its downstream targets in BCAA-mediated
insulin resistance, full consideration of the extant literature
presents a more confusing picture (reviewed in Um et al.,
2006; Avruch et al., 2009). For example, one study shows that
depletion of Leu in the diet results in reduced mTOR activity in
concert with an improvement in hepatic insulin sensitivity (Xiao
et al., 2011), whereas another shows that Leu supplementation
activates mTOR without impairing insulin action (Macotela
et al., 2011). Given the need for further investigation in this
area, the remainder of this Perspective focuses on a metabolicmodel for explaining the interaction of fatty acids and BCAA in
promoting insulin resistance.
Despite the lower rate of food intake of HF + BCAA-fed
animals, they accumulate acylcarnitine species in muscle to
the same extent as HF-fed rats (Figure 2). As described earlier,
accumulation of acylcarnitines has been interpreted by Muoio
and associates as an index of incomplete fatty acid oxidation
in mitochondria (Koves et al., 2005, 2008; Muoio and Newgard,
2008). We suggest that when BCAA accumulate in plasma as
a consequence of dietary supplementation or via other potential
mechanisms as discussed below, flux of these amino acids into
skeletal muscle and through the BCAA catabolic pathway is
increased, as also implied by the increase in C3 and C5 acylcar-
nitines in blood of obese and insulin-resistant subjects. Metabo-
lism of BCAA and/or their cognate a-ketoacids may also
increase in liver. Increased BCAA catabolism in muscle and liver
would result in increased production of propionyl CoA and
succinyl CoA. The mechanism by which accumulation of these
intermediates could contribute to incomplete oxidation of fatty
acids (as evidenced by accumulation of long, even-chained
acylcarnitines in HF + BCAA-fed animals [Figure 2]) remains to
be defined. One possibility is that in the background of a HF
diet, these substrates act to ‘‘fill’’ the TCA cycle (a process
known as anaplerosis), contributing to the accumulation of
incompletely oxidized intermediates of fatty acid and BCAA
oxidation. Under these conditions, glucose is rendered super-
fluous as an energy substrate, resulting in decreased glucose
utilization and glucose intolerance. It should be noted that
such a model is not consistent with findings of reduced levelsCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 609
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rats (Koves et al., 2008) as described earlier, but direct measures
of TCA cycle intermediates in muscle of rats fed on HF or HF +
BCAA diets have yet to be reported. Alternatively, propionyl
CoA and succinyl CoA are allosteric inhibitors of citrate synthase
(Lee et al., 1997a), and recent studies have also indicated that
mitochondrial proteins can be reversibly posttranslationally
modified and regulated by succinylation and malonylation in
addition to the more familiar mechanism of acetylation (Peng
et al., 2011; Hirschey, 2011), providing other possible mecha-
nisms for crosstalk between BCAA, fatty acid, and glucose
oxidative pathways. Also, in liver, excess carbon from BCAA
catabolism may contribute to elevated rates of lipogenesis and
gluconeogenesis. Overall, the data shown in Figure 2 suggest
that BCAA can ‘‘clog’’ the b-oxidative machinery in a manner
analogous to the effect of excess fat, even when less HF +
BCAA food is ingested compared to the HF group. Importantly,
this effect seems to require the presence of high fat in the diet,
as supplementation of standard chow diet with BCAA does not
induce insulin resistance or cause acylcarnitine accumulation
in skeletal muscle (Figure 2 and Newgard et al., 2009).
The foregoing model seems counter to traditional thinking
about pathways of BCAA catabolism, in that BCAA catabolic
flux is expected to be low in muscle, consistent with that tissue’s
abundant expression of BCATm, but much lower expression of
the branched-chain ketoacid dehydrogenase complex
(BCKDH), with an opposite ratio of expression of these enzymes
in liver (Shimomura et al., 2006). This gives rise to the commonly
held view that a large fraction of the ketoacid pool produced from
transamination of BCAA in muscle is metabolized in liver. It is
important to emphasize that this does notmean that the ketoacid
skeletons of BCAA cannot be oxidized in muscle or that
increased rates of their catabolism in muscle tissue cannot
contribute to mitochondrial overload. Our finding of increased
levels of C3 and C5 acylcarnitine species (byproducts of
BCAA, but not fatty acid catabolism) in muscle and plasma of
HF + BCAA fed rats (Figure 2, inset) and in plasma of insulin-
resistant humans (Newgard et al., 2009; Huffman et al., 2009;
Tai et al., 2010; Laferre`re et al., 2011) is consistent with this view.
How do the levels of BCAA and related metabolites rise in
obese and insulin-resistant humans? The answers are not
clearly known, but several possibilities exist. One route is
through increased protein consumption, since both the BCAA
and aromatic amino acids are essential (not synthesized de
novo in mammalian tissues). However, in both the studies of
Asian-Indian and Chinese subjects in Singapore (Tai et al.,
2010) and the longitudinal study of the Framingham cohort
(Wang et al., 2011), associations of BCAA and aromatic amino
acids with insulin resistance and risk for diabetes were not influ-
enced by protein consumption, as estimated by feeding ques-
tionnaires, suggesting that other factors are likely to contribute.
Genetic variation in expression of genes encoding key BCAA
catabolic enzymes or proteins that control protein synthesis
and turnover may be another contributor. A third possibility is
the gut microbiome, since many bacterial species are capable
of de novo synthesis of BCAA (Park and Lee, 2010) and could
contribute to alterations in circulating BCAA in the host, although
such an effect of the microbiome has yet to be demonstrated
directly.610 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.Yet a fourth possibility is suggested from several recent
studies of the interplay between adipose tissue, BCAA metabo-
lism, and glucose homeostasis. An important finding is that
subtle alterations in expression of the genes in the BCAA cata-
bolic pathway in adipose tissue can have a very significant
impact on circulating BCAA levels. This was uncovered in part
via studies of mice with adipose-specific overexpression of
GLUT-4, which resulted in modest but concerted decreases in
expression of multiple BCAA catabolic enzymes in fat tissue,
coupled with a significant increase in circulating BCAA (Herman
et al., 2010). The activity of key BCAA catabolic enzymes in
adipose tissue is also strongly influenced by obesity. For
example, BCKDH complex enzymatic activity is decreased and
phosphorylation of the E1 component of the complex is
increased in adipose tissue of Zucker-obese rats and ob/ob
mice relative to lean controls. BCATm and BCKDH gene expres-
sion is also decreased, accompanied by increased levels of
circulating BCAA in these models (She et al., 2007a). Interest-
ingly, no deficits in expression or activity of these enzymes
were reported in skeletal muscle in the same animals. In addition,
the large decrease in BCAA in response to bariatric surgery in
humans that has been described by several groups (Laferre`re
et al., 2011; She et al., 2007a) is accompanied in one study by
increased expression of BCATm and BCKDH in omental and
subcutaneous fat after surgery (She et al., 2007a), suggesting
a possible contribution of the adipose depot to re-establishment
of BCAA homeostasis with weight loss. A similar mechanism
may also be at work with application of pharmaceutical thera-
pies, as suggested in a recent study of insulin-resistant
Zucker-obese rats treated with four different thiazolidinedione
drugs with varying efficacy for control of glucose homeostasis.
Microarray analysis of multiple tissues in the treated rats re-
vealed a striking and unique correlation between the efficacy
of the drugs for glycemic control and their ability to upregulate
multiple enzymes of the BCAA catabolic pathway in adipose
tissue (Hsiao et al., 2011). Microarray studies in humans also
revealed a strong correlation between expression of BCAA
catabolic genes in adipose tissue and insulin sensitivity (Sears
et al., 2009). These data suggest that decreased catabolism of
BCAA in adipose tissue may contribute to increases in BCAA
levels in insulin-resistant states, although such an interpretation
fails to explain how C3 and C5 acylcarnitines are consistently
increased in our multiple cohorts of insulin-resistant humans
(Newgard et al., 2009; Huffman et al., 2009; Tai et al., 2010;
Laferre`re et al., 2011). We suggest that flux through BCAA cata-
bolic pathways is not universally restricted in obesity and may in
fact be enhanced in a subset of tissues, including skeletal
muscle. Flux through protein biosynthetic pathways may also
be reduced in obesity and type 2 diabetes (Pereira et al.,
2008), although it remains to be determined if such changes
are primary drivers of elevations of circulating BCAA or are
a secondary consequence of impaired insulin action on protein
metabolism.
Working Model of the Interplay of Lipids and BCAA
in Development of Insulin Resistance and Metabolic
Disease
Based on our own data and that of others in the field, we propose
that BCAA synergize with hyperlipidemia to make a contribution
Figure 3. Schematic Working Model of
Potential Crosstalk between Lipids and
BCAA in Development of Obesity-Related
Insulin Resistance
See text for details. ‘‘Anaplerosis’’ refers to reple-
tion or filling up of TCA cycle intermediates via
entry points other than acetyl CoA. TG, triglyc-
eride; IMTG, intramyocellular triglyceride; IR,
insulin receptor.
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Figure 3. In this model, the rise in circulating BCAA is driven in
part by an obesity-related decline in their catabolism in adipose
tissue. In obesity and overnutrition, readily usable glucose and
lipid substrates may obviate the need for amino acid catabolism
in adipose tissue, but the mechanism by which increased supply
of these substrates causes downregulation of the BCAA cata-
bolic enzymes remains to be explored. The fact that TZD drugs
can restore expression of the BCAA catabolic genes to normal
(Hsiao et al., 2011) may suggest a role of suppressed peroxi-
some proliferator-activated receptor g (PPARg) signaling in this
metabolic adaptation. The resultant increase in circulating
BCAA, possibly supplemented by contributions from the diet,
intrinsic genetic differences in BCAA or protein turnover, and/
or the gut microbiome, leads to an expanded pool of BCAA
and related metabolites in obese and insulin resistant subjects.
Themodel further holds that this expanded pool of BCAA ‘‘spills’’
into catabolic pathways in skeletal muscle and liver, explaining
our highly consistent observation of an increase in circulating
C3 andC5 acylcarnitines in humanswith insulin resistance (New-
gard et al., 2009; Huffman et al., 2009; Tai et al., 2010; Laferre`re
et al., 2011). As explained earlier, the further consequence of this
enhanced flux and the generation of the catabolic intermediates
propionyl CoA and succinyl CoA is to reduce the efficiency of
oxidation of fatty acids and glucose, leading to accumulation
of incompletely oxidized substrates, mitochondrial stress,
impaired insulin action, and ultimately to perturbation of glucose
homeostasis.
It is important to note that while there are a number of studies
consistent with our findings that BCAA contribute to develop-
ment of insulin resistance, there are also some that seem to
refute this conclusion. Findings consistent with ours include
the induction of insulin resistance in response to infusion of
amino acids in humans or animals, accompanied by chronicCell Metabolismactivation of mTOR, S6K1, and serine
phosphorylation of IRS1 (Krebs et al.,
2002; Tremblay et al., 2005). Moreover,
feeding of ob/ob mice with Leu-depleted
diets increases insulin sensitivity (Xiao
et al., 2011). Finally, addition of BCAA or
aromatic amino acids to cultured muscle
cells results in activation of mTOR,
impairment in insulin-stimulated phos-
phorylation of Akt/protein kinase B, and
reduced insulin-stimulated glucose up-
take (Tremblay and Marette, 2001; Saha
et al., 2010).
In contrast, other studies in mice report
either improvement in insulin sensitivity(Macotela et al., 2011; Zhang et al., 2007) or no effect (Nairizi
et al., 2009) in response to Leu supplementation. Also, global
knockout of BCATm in mice results in severe elevations of
BCAA (14- to 37-fold), coupled with resistance to diet-induced
obesity and improved glucose tolerance (She et al., 2007b).
We feel that these studies are less faithful models of human
obesity and related conditions for the following reasons. First,
Leu supplementation causes Leu to rise in the circulation, but
causes a decline in the other BCAA (Nairizi et al., 2009), thereby
failing tomimic conditions in human insulin resistance and type 2
diabetes, where all three BCAA and several other amino acids
are elevated (Newgard et al., 2009; Huffman et al., 2009; Tai
et al., 2010; Wang et al., 2011; Laferre`re et al., 2011). Second,
not all of the studies on Leu supplementation were conducted
in the context of high-fat feeding, which we have shown is
necessary to unveil effects of BCAA on insulin sensitivity in
rats. Third, mice with BCATm knockout have high rates of
protein futile cycling and increased energy expenditure (She
et al., 2007b); HF + BCAA-fed rats or obese humans do not
exhibit these changes (Newgard et al., 2009). Finally, if BCAA
were protective against metabolic disease, one would not
expect them to be elevated early in disease progression, as in
Asian subjects with insulin resistance but relatively normal
body weight (Tai et al., 2010) or in prediabetic subjects from
the Framingham and Malmo cohorts (Wang et al., 2011). Never-
theless, further studies on the mechanisms by which excess
BCAA may interfere (or not) with insulin action are warranted,
as are studies focused on deeper understanding of the crosstalk
between lipids and amino acids in development of metabolic
dysfunction.
Lipids, BCAA, and the b Cell
There may also be interactions of excess BCAA and lipids in the
development of b cell dysfunction, which drives the transition15, May 2, 2012 ª2012 Elsevier Inc. 611
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metabolic basis for the gradual dysregulation of glucose-
stimulated insulin secretion (GSIS) in type 2 diabetes is not
completely understood, in part because fatty acids and amino
acids have complex effects on the b cell. Fatty acids can serve
as secretagogues that potentiate GSIS, apparently via a combi-
nation of messengers produced during metabolism and via acti-
vation of cell-surface G protein-coupled receptors (Stein et al.,
1997; Latour et al., 2007). Islets must also maintain a minimal
supply of cellular lipids to allow stimulus/secretion coupling.
Thus, total depletion of islet triglyceride stores in rats by exper-
imental hyperleptinemia (Koyama et al., 1997) or by treatment
with the antilipolytic agent nicotinic acid (Stein et al., 1996)
results in loss of insulin secretion in response to a range of
secretagogues; this loss of function can be rescued by reprovi-
sion of fatty acids. Conversely, the dysfunctional islets in animal
models of obesity and type 2 diabetes exhibit accumulation of
stored lipids (triglyceride) and other potentially harmful lipid-
derived products (ceramides) preceding the onset of b cell
dysfunction (Lee et al., 1997b; Shimabukuro et al., 1998). Finally,
chronic exposure of islets to elevated concentrations of fatty
acids causes impairment of GSIS (Segall et al., 1999; Boucher
et al., 2004).
Amino acids have similarly complex effects on b cells. Two
of the analytes found in the principal component associated
with insulin resistance, Glu and Leu, are potent insulin secreta-
gogues, and the two analytes interact in regulating insulin secre-
tion. Glu-stimulated insulin secretion is enhanced by allosteric
activation of Glu dehydrogenase by Leu as well as metabolism
of Leu to create anaplerotic substrates (Li et al., 2003), and acti-
vating mutations in GDH cause a form of familial hyperinsulinism
(Stanley, 2009). Obese, insulin-resistant but nondiabetic humans
have elevated levels of BCAA and Glu and also exhibit an
increase in the acute insulin secretion response to glucose
(over 10 min) during a glucose tolerance test (Newgard et al.,
2009). Moreover, these analytes as well as others in the BCAA-
related principal component discussed earlier are strongly
associated with fasting insulin levels, HOMA, and C-peptide
secretion during a glucose challenge following bariatric surgery
(Laferre`re et al., 2011). Taken together, these findings suggest
that chronic elevations in BCAA and related metabolites may
synergize with a similar slow rise in circulating fatty acids to drive
a state of chronic hyperinsulinemia. This constant secretory
pressure on the b cell may ultimately contribute to b cell dysfunc-
tion by causing endoplasmic reticulum stress (see Muoio and
Newgard, 2008 for review). The same amino acids may con-
tribute to the rapid improvement in glycemic control in response
to bariatric surgery, in part by tempering the chronic hyperinsu-
linemia.
Concluding Remarks
In summary, recent studies from several laboratories have re-
kindled interest in the potential role of protein and amino acid
metabolism in development of metabolic disease. In particular,
the multiple new examples of strong associations between
BCAA and related metabolites with incidence, progression,
and remission of insulin resistance, type 2 diabetes, and car-
diovascular disease provide the impetus for gaining better
understanding of the potential synergies between this group612 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.of metabolites and lipids in development of metabolic dysfunc-
tion in multiple tissues. It is hoped that the working models
advanced here will help in the design of experiments to further
pursue the mechanistic underpinnings of such crosstalk in the
future.
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